What We’re Reading: Prostate Cancer Study Halted; Nervous System Complications After COVID-19; Health Risks From Erythritol
Merck ends a prostate cancer study involving pembrolizumab; a little-known nervous system condition is affecting some patients after COVID-19 infection; the artificial sweetener erythritol might increase risk of heart attack and stroke, according to a preliminary study.
Merck Discontinues Prostate Cancer Study
Merck has announced that it will stop a late-stage drug trial of combination therapy with checkpoint inhibitor pembrolizumab (Keytruda) for prostate cancer after interim data showed that it wasn’t likely to meet the main goals of the study,
Nervous System Disease Rising After COVID-19 Infections
A condition called postural orthostatic tachycardia syndrome (POTS) is on the rise following COVID-19 infection, but because it is not well understood in the medical community, most patients are dismissed as having anxiety and have significant delays in treatment,
Artificial Sweetener Might Increase Risk of Heart Attack, Stroke
A preliminary
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025
- Modest Reductions in PrEP Coverage Result in Avoidable HIV Infections
September 17th 2025